Huang J et al. reported that the serum levels of carcinoembryonic antigen (CEA) and CA125 predict progression-free survival (PFS) and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) receiving first-line immunotherapy (26). The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.